All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, August 10, 2022
Home » Blogs » BioWorld Perspectives » The FDA: Stuck in 1984

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

The FDA: Stuck in 1984

Jan. 23, 2012
By Mari Serebrov
No Comments

While 2012 has dawned everywhere else in the world, it’s still 1984 at the FDA. With its Bad Ad program, whistle-blower suits and spotters of conference crimespeak serving as its globalwise eyes and ears, the agency has adopted Big Brother (BB) tactics to promote goodspeak among drugmakers while crimestopping off-label promotion, bringing new life to George Orwell’s newspeak.

In the newthink of the FDA, quality of life (QOL) is one of those doubleplusungood phrases that a biotech dare not utter – unless it has conducted a doubleplushuge, FDA-approved, randomized, controlled, double-blind pivotal study, including doubleplusvulnerable populations and diverse subpopulations, to demonstrate a statisticwise improvement in the primary endpoint of QOL as measured by patient-reported outcomes on the U.S. Standardized Scale of Life Quality Factors. QOL, after all, is an indication – just like cancer or rheumatoid arthritis.

Once the data are in, the FDA would convene an advisory committee of unconflicted goodthinkers with a bellyfeel for QOL issues. This Good Life Advisory Committee (GLAC) would be asked to define QOL and weigh the good and the ungood of whether the study data support an improved QOL indication. For instance, was the follow-up period long enough to establish longwise improvement? Did the trial include patients with comorbidities such as unhappiness, drug ungood use or alcohol doubleplususe?

Once past the GLAC, the bigwise challenge for drugmakers would come after the FDA approves the indication. That’s when BB will doubleplusstart watching, using its Sentinel Initiative and FDA Adverse Event Reporting System to trend ungood QOL events such as unexplained frowning, occasional bouts of sadness, tearing of the eyes, flashes of frustration, weight gains, unplanned pregnancies, job losses, relationship problems, etc.

But since the FDA is unlikely to approve a drug for QOL, drugmakers need to speedwise forget their oldthink and become goodthinkful FDA newspeakers.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 9, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 9, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing